ଆଟୋଭାକୋନ

ଆଟୋଭାକୋନ
Clinical data
Trade names	Mepron
AHFS/Drugs.com	monograph
MedlinePlus	a693003
Pregnancy; category	US: C (Risk not ruled out) ; ;
Routes of; administration	By mouth
Legal status
Legal status	UK: POM (Prescription only) ; US: ℞-only ;
Pharmacokinetic data
Elimination half-life	2.2–3.2 days
Identifiers
	IUPAC name trans-2-[4-(4-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione;
ECHA InfoCard	100.158.738
Chemical and physical data
Formula	C22H19ClO3
Molar mass	୩୬୬.୮୪ g·mol−1
3D model (JSmol)	Interactive image;
Melting point	216 to 219 °C (421 to 426 °F)
	SMILES OC=2C(=O)c1ccccc1C(=O)C=2[C@@H]3CC[C@H](CC3)c4ccc(Cl)cc4;
	InChI InChI=1S/C22H19ClO3/c23-16-11-9-14(10-12-16)13-5-7-15(8-6-13)19-20(24)17-3-1-2-4-18(17)21(25)22(19)26/h1-4,9-13,15,26H,5-8H2/t13-,15- ; Key:KUCQYCKVKVOKAY-CTYIDZIISA-N ;
(verify)

ଆଟୋଭାକୋନ, ନିମୋସାଇଟିସ୍ ଏକ ଔଷଧ ଯାହା ନିମିସାଇଟିସ ଜିରୋଭେସି ନିମୋନିଆ (ପିସିପି/PCP), ଟକ୍ସୋପ୍ଲାଜୋମୋସିସ ଏବଂ ବାବେସିଓସିସ୍ ରୋଗର ଚିକିତ୍ସା ତଥା ପ୍ରତିରୋଧ ପାଇଁ ବ୍ୟବହୃତ ହୁଏ । ^[୨] ^[୩] ପିସିପି ପାଇଁ ଏହା ବ୍ୟବହୃତ ହୁଏ ଯେଉଁମାନେ ଟ୍ରାଇମେଥୋପ୍ରିମ୍ / ସଲଫାମେଥୋକ୍ସାଜୋଲ ନେଇପାରିବେ ନାହିଁ । ^[୨] ଏହା ପାଟିଏ ଦିଆଯାଏ ।| ^[୨]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମୁଣ୍ଡବିନ୍ଧା, ଜ୍ୱର, ଉଦ୍‌ବେଗ, ଶୋଇବାରେ ଅସୁବିଧା, ସ୍ପଷ୍ଟ ସ୍ୱପ୍ନ, ବାନ୍ତି, ତରଳ ଝାଡ଼ା, ଚର୍ମ ଦାଗ ଏବଂ ଗଲୁ ଅନ୍ତର୍ଭୁକ୍ତ । ^[୪] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଯକୃତ ସମସ୍ୟା ଏବଂ ଆଞ୍ଜିଓଡେମା ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ | ^[୨] ଗର୍ଭାବସ୍ଥାରେ ଏବଂ ସ୍ତନ୍ୟପାନରେ ସୁରକ୍ଷା ଅସ୍ପଷ୍ଟ ଅଟେ। ^[୫] ଏହା ଏକ କ୍ୱିନୋନ୍, ବିଶେଷ ଭାବରେ ଏକ ନାଫଟୋକ୍ୱିନୋନ । ^[୪] ^[୨]

୧୯୯୨ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା ବ୍ୟବହାର ପାଇଁ ଆଟୋଭାକୋନ ଅନୁମୋଦିତ ହୋଇଥିଲା। ^[୪] ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ। ^[୬] ଯୁକ୍ତରାଜ୍ୟରେ ୫୦ ମିଗ୍ରା ୭୫୦ ମିଗ୍ରାର ୫୦ ମାତ୍ରା ଔଷଧର ମୂଲ୍ୟ ୨୦୨୧ ସୁଦ୍ଧା ପ୍ରାୟ ୪୭୦ ପାଉଣ୍ଡ ଅଟେ। ^[୬] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ମୂଲ୍ୟ ପ୍ରାୟ ୨୨୦ ଡଲାର ଅଟେ। ^[୭]

ଆଧାର

↑ "Wellvone 750mg/5ml oral suspension - Summary of Product Characteristics (SmPC)". (emc). 28 November 2019. Archived from the original on 24 October 2020. Retrieved 18 September 2020.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ "Atovaquone Oral SUSPENSION- atovaquone suspension". DailyMed. 10 December 2019. Archived from the original on 7 August 2020. Retrieved 18 September 2020.
↑ "Atovaquone Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 3 June 2021. Retrieved 16 January 2022.
↑ ^୪.୦ ^୪.୧ ^୪.୨ "Atovaquone". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 6 May 2021. Retrieved 16 January 2022.
↑ "Atovaquone (Mepron) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 28 November 2020. Retrieved 16 January 2022.
↑ ^୬.୦ ^୬.୧ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 641. ISBN 978-0857114105.
↑ "Atovaquone Prices and Atovaquone Coupons - GoodRx". GoodRx. Retrieved 16 January 2022.

[1] "Wellvone 750mg/5ml oral suspension - Summary of Product Characteristics (SmPC)". (emc). 28 November 2019. Archived from the original on 24 October 2020. Retrieved 18 September 2020.

[PI2022-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ "Atovaquone Oral SUSPENSION- atovaquone suspension". DailyMed. 10 December 2019. Archived from the original on 7 August 2020. Retrieved 18 September 2020.

[AHFS2022-3] "Atovaquone Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 3 June 2021. Retrieved 16 January 2022.

[Liv2022-4] ୪.୦ ^୪.୧ ^୪.୨ "Atovaquone". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 6 May 2021. Retrieved 16 January 2022.

[5] "Atovaquone (Mepron) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 28 November 2020. Retrieved 16 January 2022.

[BNF81-6] ୬.୦ ^୬.୧ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 641. ISBN 978-0857114105.

[7] "Atovaquone Prices and Atovaquone Coupons - GoodRx". GoodRx. Retrieved 16 January 2022.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]